A summary of the intervention received by participants randomised to either intervention arm is presented in Table S1 . Overall, 665 (54.5%) participants completed the intervention, whereas 344 (28.2%) did not start intervention sessions and 211 (17.3%) started but did not complete intervention sessions. Differences in intervention receipt were significantly different between the intervention arms (χ 2 (2)=38.30, p<0.001).
For all participants who started the intervention (n=843), a mean of 8.2 (3.2) sessions (median=9, IQR=7-11), including the introductory session, were received. The differences (tested with Mood's median test) in attendance between treatment arms is given in Table S2 , with the individual arm attending significantly more sessions (χ 2 (1)=85.71, p<0.001).
Participants attended a mean of 4.8 (1.9; median=6, IQR=4-6) of the 6 intensive sessions, and 2.4 (1.7; median=3, IQR=0.5-4) of the four maintenance sessions. Participants in the individual arm attended significantly more maintenance sessions (χ 2 (1)=95.51, p<0.001) than participants in the group arm, but there was no difference for intensive sessions (χ 2 (1)=1.14, p=0.29). A comparison of attendance between the arms and session types is also presented in Table S2 . 
Time to intervention commencement
There were unexpected delays to intervention commencement. Date of intervention commencement was missing for 35 (2.9%) participants. We endeavored to start the intervention within six months of randomisation, and this was possible for 986 (83.2% of 1185) participants: 561 (82.3% of 682) in the group arm and 425 (84.5% of 503) in the individual arm. The time between randomisation and intervention start for participants randomised to each intervention arm is illustrated in Figure S1 . Participants randomised to receive the intervention (group or individual arms) waited a mean of 3.12±2.70 months (min=0.16, max=15.21, median=2.07, IQR=0.92-4.99) from randomisation to their scheduled introductory session. The wait time did not differ between the group (3.17±2.78 months, n=682) and individual arms (3.04±2.59 months, n=503; t(1120.5)=0.83, p=0.41).
We investigated the association between delays to intervention commencement and the number of sessions attended. We observed a moderate negative correlation in the group arm (r(680)=-0.20, p<0.001), but not in the individual arm (r(501)=-0.03, p=0.57). The difference in correlations between the arms was significant (z=2.94, p=0.003).
Figure S1. Time between randomisation and intervention commencement (session 0) by intervention arm.

Intervention duration
For those participants attending at least one of Sessions 1-10 (n=782), we calculated the time between Session 0 and the final session attended. Across intervention arms, the mean time between Session 0 and the final session was 330.6±173.8 days (min=6, max=808, median=366, IQR=231-440; dates were unavailable for one patient (0.1%)). Time between Session 0 and final session was significantly longer in the individual arm (355.6±173.1 days, n=373) than in the group arm (307.8±171.4 days, n=408; t(771.4)=3.87, p<0.001).
Participant adherence to intervention
After the completion of each intervention session, the health trainer was responsible for recording: (a) if the patient set a target for that session (yes/no); and (b) if that target was achieved (coded as no/partially/fully). Session 0 was not included as participants were not asked to set goals for that session. Of the 1220 participants randomized to the intervention arms, 774 had adherence data available (63.44%). Of those, 407 (58.39% of those randomized) were in the group arm and 367 (70.17% of those randomized) in the individual arm.
The 774 participants attended a total of 5932 sessions. Table S3 shows the rate of targets set overall and by intervention arm. The overall rate of targets set differed significantly between arms (χ 2 (1)=6.12, p=0.01) but the distribution of targets set at each session did not differ significantly between arms (χ 2 (9)=16.18, p=0.06; data are not shown). For each target set, the health trainer also recorded if the participant achieved it; achievement was rated as 'not at all', 'partially', or 'fully'. Table S3 shows the number of targets achieved by intervention arm and in total; the distribution of targets achieved (excluding missing data) differed significantly between arms (χ 2 (2)=7.25, p=0.03). The rate of target achievement differed by session number (χ 2 (18)=116.99, p<0.001; data are not shown).
For the MI components for the health trainers, the average MITI scores for the spirit and reflection-to-question domains exceeded proficiency thresholds (3.5 (0.7) and 1.3 (0.9), respectively) and scores for the other three domains were slightly below the proficiency 
Loss to follow-up
Participants were not seen at follow-up for one of three reasons: (i) they had withdrawn from the study, (ii) they had died, or (iii) they were non-contactable at follow-up due date (attempts were made to contact the participant up to six months after the due date). Participants randomised to either of the intervention arms but who did not take part in the intervention did not necessarily withdraw from the study, and their data are included at follow-up to carry out the ITT analysis. Table S4 shows loss to follow-up at both 12-and 24-month follow-ups and the reasons for withdrawal given. Those who were permanently lost to follow-up at 12 months (withdrawn/died) were not contacted again at 24 months, whereas those who were non-contactable at 12 months were contacted again at 24 months. We exceeded the target follow-up of 83% required by the original sample size calculation. The total loss to follow-up across all arms of the study at 12 months was 11.8%; 15.2% for the group arm, 11.9% for the individual intervention arm and 7.3% for the UC arm. The total loss to follow-up across all arms of the study at 24 months was 16.8%; 18.4% for the group arm, 19.7%
for the individual arm and 11.9% for the UC arm. Data were collected for 91.6% of all participants for at least one of 12-or 24-month follow-up, and for 79.7% of participants at both 12 and 24 months. The differences in loss to follow-up between the treatment arms were significant at 12 month (χ 2 (2)=17.99, p<0.001) and 24 month follow-up (χ 2 (2)=13.39, p=0.001).
Withdrawal rates differed significantly between treatment arms at both 12-(χ 2 (2)=27.08, p<0.001) and 24-month follow-up (χ 2 (2)=15.98, p<0.001).
Accelerometer data completeness
The remaining participants did attend follow-up appointments but did not necessarily complete accelerometer wear for collection of PA outcomes. Table S5 provides details on the amount of accelerometer data collected by trial arm at each time point. The required PA data at baseline was at least five days of ≥540 minutes accelerometer wear. A number of participants did not wear the accelerometer for the sufficient amount of time at baseline and, therefore, were randomised in error. In the original analysis plan we stated that we included those with at least four days data in the primary analysis to limit exclusions. However, after discussions with the statistician of the TSC, we included all participants to minimize loss of power and to avoid inducing a potential bias. In agreement with the TSC, we used for all time points the wearable data points if participants wore the accelerometer at least one full day (≥540 minutes).
Otherwise, the data were considered missing.
The total missing activity data across all arms of the study at baseline was 0.5% (n=8) and at 12 months it was 18.6%: 20.1% for the group arm, 20.1% for the individual arm and15.1% for the UC arm, χ 2 (2)=5.9, p=0.052. The total missing activity data across all arms of the study at 24 months was 20.6%: 22.1% for the group arm, 23.3% for the individual arm and 15.9% for the UC arm, χ 2 (2)=10.4, p=0.006. At least one activity follow-up measurement was available for 88.1% of the study participants: 86.4% for the group arm, 86.6% for the individual arm and 91.8% for the UC arm, χ 2 (2)=9.7, p=0.008. observed and imputed data was used for the primary analyses. The single imputation method treats imputed values as if they were observed and hence ignores the uncertainty of the correct value. However, Catellier et al. demonstrated that EM imputation methods with intermittent missing activity data produced similar results as multiple imputation, as simulation studies showed that there were no differences in estimates of means and standard deviations. Both methods produced unbiased under missing completely at random conditions (with EM imputation sometimes performing slightly better) and hence their use is regarded as standard for intermittent missing days of activity data. 2, 3 Day of the week, month, and year were included as indicator variables in the imputation model. Activity data will be imputed within each treatment arm separately. Standard clinical and demographic variables were included as potential predictors.
Predictors of missing outcome data at 12 and 24 months
In addition to missing the follow-up assessment, activity data were also missing because accelerometers were not worn sufficiently long enough. Two patients did not provide weight data at 24 months. An analysis of missing outcome data was therefore done in addition to missing attendance. A stepwise logistic regression with baseline variables, treatment arm, borough at baseline and potential predictors of missing outcome data at 12 and 24 months for weight and PA separately revealed that education, smoking status, PHQ-9 depression score and treatment arm are the most important predictors. However, only little variation was explained by the models (<2.5% pseudo-R 2 ). Education, smoking status, and PHQ-9 depression score were included as predictors of missingness in a sensitivity analyses to assess potential bias due to missing outcome data. Table S6 presents baseline characteristics of participants with missing data at 12-month followup and those who attended 12-month follow-up and participants with missing data at 24-month follow-up and those who attended 24-month follow-up. 
Sensitivity Analyses Sensitivity analysis adjusting for imbalances on baseline characteristics
No imbalances were observed on any of the pre-specified baseline characteristics, therefore, a sensitivity analysis adjusting for these variables was not done for either of the primary outcomes.
A total of 14 sensitivity analyses were conducted for each (except for two occasions) of the primary outcomes:
1. Adjusting for partially nested random effect for therapist. 2. Adding therapist and general practice as random factors and exchangeable residual covariance matrix. 3. Removing potential outliers (removed n=12 for weight; n=6 for PA). 4. Only including patients with BMI>25kg/m 2 (analysed n=2298 for weight; n=2159). 5. Adjusting for treatment compliance (including patients in arms A/B that attended at least one intervention session; analysed n=2427 for weight; n=2305 for PA). 6. Adjusting for the delay in intervention start (continuous variable). 7. Adjusting for the unblinding of the research assistant at each follow-up appointment (binary variable). 8. Adjusting for the number of accelerometer wear days at baseline (>3 days, binary variable). 9. Adjusting for the number of accelerometer wear days at baseline (>5 days, binary variable). 10. Adjusting for the number of valid accelerometer wear days at baseline (≥540 minutes, continuous variable). Not completed for weight. 11. Adjusting for the number of accelerometer wear days at each follow-up appointment (continuous variable). Not completed for weight. 12. Adjusting for a BMI score <25 kg/m 2 at baseline (binary variable). 13. Adjusting for a QRisk2 score ≥20.0% at baseline (binary variable). 14. Adjusting for predictors (PHQ-9, smoking status, education) of missing outcome data.
Tables S9-S12 present the output of the primary and sensitivity analyses for each of the primary outcomes, following the numbering above. None of the above sensitivity analyses altered our conclusions for either of the primary outcomes.
The secondary comparison ('group versus individual') was assessed on a 5% significance level. 
12-month follow-up
Individual -UC 8. Adjusting for the number of accelerometer wear days at baseline (>3 days, binary variable). 9. Adjusting for the number of accelerometer wear days at baseline (>5 days, binary variable). 10. Adjusting for the number of valid accelerometer wear days at baseline (≥540 minutes, continuous variable). Not completed for weight. 11. Adjusting for the number of accelerometer wear days at each follow-up appointment (continuous variable). Not completed for weight. 12. Adjusting for a BMI score <25 kg/m 2 at baseline (binary variable). 13. Adjusting for a QRisk2 score ≥20.0% at baseline (binary variable). 14. Adjusting for predictors (PHQ-9, smoking status, education) of missing outcome data. 
Cost-effectiveness
The number and percentage of participants using specific services or groups of services are shown in Table S13 . In the 12-month period prior to baseline assessment the use of all services was very similar between the three treatment arms. There were relatively few people attending A&E or day hospitals or being admitted as inpatients. About half of each group had outpatient contacts and nearly everyone had community contacts. This was particularly due to GP visits.
In the 12 months prior to the 12-month follow-up, around two-thirds of the group arm and threequarters of the individual arm received the relevant intervention. Visits to A&E and outpatient attendances had increased slightly from baseline but there were no clear differences between treatment arms. These patterns were again observed in the 12-month period prior to the second follow-up, although there was again a slight increase in the proportions having outpatient attendances.
For those with specific service contacts, the average number of contacts is shown in Table S14 .
At baseline, community services were used more intensely than other services. The inpatient contacts refer to number of days in hospital. It can be seen that there are no major differences between arms. The data for the one-year follow-up show that the individual arm had slightly more intervention contacts than the group arm. Those admitted to hospital from the individual arm had more days in hospital than the other two arms. There were no clear differences between arms in the period up to the 24-month follow-up.
Service costs (including zero costs for non-users) were similar for inpatient care, outpatient attendances, and community contacts (Table S15 ). Costs of services did not differ markedly between arms, although inpatient costs were somewhat higher for the individual arm at the 12month follow-up and lower at the 24-month follow-up. The intervention cost was highest for those in the individual arm.
Compared to UC, total costs at baseline were on average £151 more for the group arm (95% CI=-£27 to £328) and £55 more for the individual arm (95% CI=-£96 to £203). The group arm costs were one average £95 more than those for the individual arm (95% CI=-£93 to £299). 
(1114)
We could not calculate the cost of lost employment as these data were not adequately recorded. The group arm was less effective than UC and more expensive. As such it was dominated.
Individual was more expensive and more effective. The ICER was £55,625 per QALY (£356 divided by 0.0064 QALYs). Uncertainty around the estimates are shown in the cost-effectiveness planes ( Figures S2 and S3 ). In Figure SXX Figure S4 shows the cost-effectiveness acceptability curves where all three arms are compared for different values placed on a QALY gain. When a zero value is placed on a QALY, UC has by far the highest probability of being the most cost-effective option (in this situation, only costs are relevant and UC is less expensive). As the value on a QALY is increased, the probability that the individual arm is the most cost-effective option increases steadily while the other two arms see a fall in the probability that they are the most cost-effective. This is to be expected as the individual arm is more expensive and more effective than the other options and as the effect (i.e. increased QALYs) is valued more it increasingly offsets the cost. However, at a value of £30,000 (above which NICE is likely to decide an intervention is not cost-effective) the individual arm has a 37.4% likelihood of being the most cost-effective option compared to 58.1% for UC. At this value, the group arm has a likelihood of 4.5% of being the most cost-effective option.
Figure S4. Cost-effectiveness acceptability curves.
In sensitivity analyses, the intervention costs were increased and decreased by 25% and 50% respectively to reflect different staff grades delivering the interventions. When intervention costs were reduced by 25%, the group arm had costs that were on average £188 more than for UC while costs for the individual arm were £395 more than for UC. The differences when intervention costs were increased by 50% were £204 and £434 respectively. Not surprisingly When intervention costs are reduced by 25%, the group arm has costs that are on average £157 more than for UC. With fewer QALYs, UC is still dominant. Individual is now £317 more than for UC resulting in a cost per QALY of £49,531. With a reduction of 50%, the group arm still has higher costs than UC (by £141) and so continues to be dominated while the individual arm has costs that are £278 higher resulting a cost per QALY of £43,438. 
Adverse events
